We Offer Worldwide Shipping
Login Wishlist

Armillarisin A

$320

  • Brand : BIOFRON

  • Catalogue Number : BN-O1467

  • Specification : 98%(HPLC)

  • CAS number : 53696-74-5

  • Formula : C12H10O5

  • Molecular Weight : 234.2

  • PUBCHEM ID : 5320192

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1467

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

234.2

Appearance

Botanical Source

Structure Type

Category

SMILES

CC(=O)C1=CC2=C(C=C(C=C2OC1=O)O)CO

Synonyms

3-Acetyl-5-hydroxylmethyl-7-hydroxycoumarin/2H-1-Benzopyran-2-one, 3-acetyl-7-hydroxy-5-(hydroxymethyl)-/3-acetyl-7-hydroxy-5-(hydroxymethyl)chromen-2-one/3-Acetyl-7-hydroxy-5-(hydroxymethyl)-2H-chromen-2-one/Armillarisin A

IUPAC Name

3-acetyl-7-hydroxy-5-(hydroxymethyl)chromen-2-one

Density

1.5±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

227.2±23.6 °C

Boiling Point

565.0±50.0 °C at 760 mmHg

Melting Point

250-255ºC

InChl

InChl Key

XVZWWNMZVZWQKU-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:53696-74-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28463673

Abstract

Object: To discover whether cirrhotic portal hypertension patients with symptomatic cholelithiasis would benefit from cholecystolithotomy combined with Armillarisin A in the authors hospital. Methods: Sixty-one patients with cirrhotic portal hypertension and symptomatic gallstone disease who underwent either cholecystolithotomy combined with Armillarisin A (group A) or cholecystectomy (group B) for cholelithiasis from Feb 2007 to March 2011 were retrospectively reviewed. These patients were undergoing simultaneous procedure for esophageal varices. The operation-relevant information, change of laboratory examination data, postoperative complications and symptoms were analyzed. Results: There were no significant differences between group A and group B in mean operative time, intraoperative blood loss, time to resume diet postoperatively and length of hospital stay (P 0.05). The hepatic function biochemical profile and Child-Pugh’™s score at 2 weeks and 1 month after operations were both altered significantly less in group A than in group B (ALT, 0.008, 0.011; AST, 0.006, 0.003; Child-Pugh’™s score, 0.010, 0.016, respectively). However, at 6 months postoperatively, the changes were not significant (P 0.05). Except for gallstone recurrence and wound infection, occurrences or development of postoperative complications including biliary fistula, liver failure and subphrenic infection showed significant differences between the two groups (P = 0.037, P = 0.041, P = 0.019, respectively). After a mean follow-up of 4.2 years, all patients remain alive. Twenty-seven patients in group A (93%) are free of biliary symptoms.

Conclusion: Cholecystolithotomy combined with using Armillarisin A is a useful treatment for symptomatic gallstones in patients with cirrhotic portal hypertension who are at high risk for cholecystectomy. It preserves gallbladder function and reduces the possibility of liver failure; moreover the rate of recurrent gallstones are relatively low.

Celsius.

Title

Cholecystolithotomy Combined Armillarisin A Versus Cholecystectomy in Cirrhotic Portal Hypertension Patients With Symptomatic Cholelithiasis

Author

Yang Fei, Wei-Qin Li, Guang-Quan Zong, Jian Chen, Wei Wang

Publish date

Mar-Apr 2017

PMID

25420534

Abstract

To study the therapeutic effect of Armillarisin A on patients with ulcerative colitis (UC) and on serum IL-1β and IL-4, sixty patients with UC were randomly divided into three groups: Armillarisin A treatment group (Group I), Armillarisin-combined hormone therapy group (Group II), and hormones treatment as the control group (Group III). Patients in Group I received Armillarisin A 10 mg enema in 100 ml saline. Patients in Group II received Armillarisin A 10 mg and dexamethasone 5 mg enema in 100 ml saline. Patients in Group III received only dexamethasone 5 mg enema in 100 ml saline. The therapeutic efficacy and serum levels of IL-4 and IL-1β were observed. After 4 week treatment, the total effective rates were 90.0 % in Group I and 95.0 % in Group II. Both are higher than it in control group, which was 70.0 %. The serum levels of IL-4 in Groups I and II were significantly higher than it in control group. Compared to IL-4 levels before treatment, the levels of IL-4 after treatment were significantly higher in both Groups I and II. The serum levels of IL-11β were significantly decreased in Groups I and II in comparison to it in control group. Compared to the levels of IL-1β before treatment, the levels of IL-1β were significantly decreased. Armillarisin A shows a significant effect in treating UC. It helps increase IL-4 and lower IL-1β and the mechanism may be related to the body’s immunity regulation.

KEYWORDS

Armillarisin; IL-1β; IL-4; Ulcerative colitis.

Title

The Effects of Armillarisin A on Serum IL-1β and IL-4 and in Treating Ulcerative Colitis

Author

Ping Wu 1, Yonggao Guo 2, Fangyuan Jia 2, Xiuli Wang 2

Publish date

2015 May

PMID

24916899

Abstract

1. This study is performed to investigate liver microsomal glucuronidation of Armillarisin A (A.A), an effective cholagogue drug, aiming at characterizing the involved UDP-glucuronosyltranferases (UGT) and revealing potential species differences. 2. A.A glucuronidation in human liver microsomes (HLM) generates one metabolite (M2) glucuronidated at the phenol hydroxyl group, obeying Michaelis-Menten kinetic model. Multiple isoforms including UGT1A1, 1A7, 1A9 and 2B15 can catalyze A.A glucuronidation. Kinetic assays and chemical inhibition studies both demonstrate that UGT1A9 is responsible for A.A glucuronidation in HLM. A.A glucuronidation in Cynomolgus monkey microsomes (CyLM) also follows Michaelis-Menten model, but can additionally catalyze the traced glucuronosyl substitution at the alcohol hydroxyl group (M1). The reactions in liver microsomes from Sprague-Dawley rats (RLM), ICR/CD-1 mouse (MLM), Beagle dog (DLM) all display biphasic kinetics and only M2 is detected. HLM, RLM and CyLM exhibit very similar catalytic activities towards A.A glucuronidation, with the intrinsic clearance values of respective 38, 37 and 37 μL/min/mg, which are much higher than MLM and DLM. 3. This in vitro study indicates that UGT1A9 acts as a major contributor to A.A glucuronidation in human liver, and the reaction displays large species differences.

KEYWORDS

Armillarisin A; UDP-glucuronosyltranferases; liver microsomal glucuronidation; species difference.

Title

In Vitro Glucuronidation of Armillarisin A: UDP-glucuronosyltransferase 1A9 Acts as a Major Contributor and Significant Species Differences

Author

Dongxue Sun 1, Liangliang Zhu, Ling Xiao, Yangliu Xia, Guangbo Ge, Yunfeng Cao, Yan Wu, Jun Yin, Ling Yang

Publish date

2014 Nov;


Description :

Empty ...